MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
Ryan Allway January 4th, 2022 Psychedelics – Last subject completed study in late 2021 with topline results expected in early 2022 – – Results to inform design of Phase 2a study in individuals undergoing supervised opioid withdrawal – NEW YORK, Jan. 4, 2022 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED),... Read more
SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders
Patent Extends Protection for its Novel Compounds and Methods Already granted in Australia and Japan TEL AVIV, Israel, Jan. 4, 2022 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company” or “SciSparc”), marks... Read more
Optimi Health Receives Dealers License Inspection and Introduces Quality Assurance Department
Ryan Allway December 21st, 2021 Psychedelics VANCOUVER, British Columbia, Dec. 21, 2021 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional as well as novel psychedelic compounds focused on the health and wellness sector, is... Read more
Maya Health Raises $4.3 Million to Decentralize Psychedelic Medicine Research
Ryan Allway December 17th, 2021 Psychedelics December 17, 2021 –  Maya Health (Maya PBC), the leading real-world data platform connecting psychedelic therapists, patients, and researchers, announced its successful raise of $4.3 million in its first investment rounds. The funding includes an $800,000 angel round and a subsequent $3.5 million in... Read more
Silo Wellness Announces Latest Psychedelic Retreat Offerings
Ryan Allway December 16th, 2021 Psychedelics Montego Bay, Jamaica–(Newsfile Corp. – December 16, 2021) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or “the Company”), a leading global psychedelics company, today unveiled a new series of psilocybin-assisted wellness retreats for 2022. Set in Jamaica’s idyllic... Read more
Entheon Biomedical Announces EEG Patent Application & Provides Research Update
Ryan Allway December 16th, 2021 Psychedelics Vancouver, British Columbia–(Newsfile Corp. – December 16, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction... Read more
MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application
Ryan Allway December 15th, 2021 Psychedelics VANCOUVER, BC, Dec. 15, 2021 /CNW/ – MYND Life Sciences Inc. (“MYND” or the “Company“) (CSE: MYND) (OTC: MYNDF) is pleased to announce it has completed the National Phase filing of its Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional patent applications that describe:... Read more
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders
Ryan Allway December 15th, 2021 Psychedelics – Expands intellectual property portfolio and strengthens position as leading innovator in developing putative psychedelic compounds – TORONTO–(BUSINESS WIRE)– Cybin Inc. ( NEO:CYBN) ( NYSE American:CYBN) (“ Cybin” or the “ Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM” today announced that it has been awarded a... Read more
Revitalist Executes on Vision to Become a Clinical Leader in Psychedelics
Ryan Allway December 10th, 2021 Psychedelics, Top Story Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) set out to build a nationwide network of psychedelic-assisted psychotherapy clinics in 2018. Since then, the company has grown its footprint to ten clinics across six states exceeding 60,650 sq.... Read more
Jupiter Wellness Signs Definitive Agreement to Merge with Next Frontier Pharmaceuticals, a Leading Drug Developer and Manufacturer of Synthetic Cannabinoid Pharmaceuticals
Ryan Allway December 9th, 2021 Owner of SYNDROS®(dronabinol), the only US-based FDA approved CII Tetrahydrocannabinol (THC), a liquid cannabinoid used in adults to treat: Chemotherapy Induced Nausea and Vomiting (CINV) associated in adult patients who have failed to respond adequately to conventional antiemetic treatments; and Anorexia associated with weight... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )